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Abstract
To characterize and compare acid suppression (pharmacodynamics) and pharmacokinetics of IV famotidine and ranitidine in critically ill children at risk
for stress gastritis. Single‐blind, randomized study in PICU patients 6 months to 18 years requiring mechanical ventilation with continuous gastric pH
monitoring, randomized to IV famotidine 12mg/m2 or ranitidine 60mg/m2when gastric pH< 4.0>1 hour with serial blood sampling following first dose.
Twenty‐four children randomized to either famotidine (n¼ 12) or ranitidine (n¼ 12). Sixteen out of twenty‐four completed both PK and PD study arms
(7/12 famotidine; 4.7 3.4 years; 9/12 ranitidine; 6.6 4.7 years; p¼ 0.38). Time to gastric pH 4.0 and total time pH above 4.0 similar with no difference
in pH at 6 and 12 hours (p> 0.2). No difference between drugs in clearance, volume of distribution and half‐life (p> 0.05). Ratio of AUCpH toAUCdrug
concentration 0–12 hours after first dosewas significantly greater for famotidine (0.06849 0.01460 SD) than ranitidine (0.02453 0.01448; p< 0.001)
demonstrating greater potency of famotidine. pH lowering efficacy of both drugs is similar. Greater potency of famotidine may offer clinical advantage
due to lower drug exposure and less frequent dosing to achieve same pH lowering effect.
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Gastric acid secretion is essential for development of stress
induced gastroduodenal lesions in critically ill children.1
Under conditions of stress, ischemia leads to mucosal
acidiﬁcation and results in ulceration.1,2 Patients receiving
mechanical ventilation for longer than 2 days are at high
risk for stress induced bleeding.2,3 Stress ulcers leading to
gastrointestinal bleeding occur in 5–20% of critically ill
patients.3 Despite availability of proton pump inhibitors
and limited evidence to guide agent selection and dosing,
H2 receptor blocker prophylaxis is administered routinely
in the pediatric intensive care unit (PICU).4–8
Histamine receptor blockers inhibit histamine‐stimu-
lated acid secretion by reversible, competitive inhibition
of H2 receptors of the parietal cells.
3 Ranitidine was the
second histamine receptor blocker to be released after
cimetidine and has claimed the majority of hospital use
replacing cimetidine secondary to less microsomal
enzyme based drug interactions and dosing ease.4–6
Famotidine has been used less frequently primarily
secondary to expense, yet may present advantages in
terms of potency and decreased dosing frequency.
Famotidine has been shown to be 7.5 times more potent
than ranitidine in suppressing acid with a longer duration
of action in adults.4,5 Data on IV famotidine use in the
PICU setting is limited, particularly in comparison to other
H2 receptor blocker therapy.8–12 Altered biodisposition of
H2 receptor blockers in children compared to adults has
been demonstrated secondary to immature hepatic and
renal function.9–15 In addition to effects of immaturity,
children in PICU often have organ function compromised
by disease, further affecting pharmacokinetics and
pharmacodynamics of drug therapy.11–18 A paucity of
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data persists regarding the comparative efﬁcacy and
pharmacokinetics of these agents in a PICU population. In
this study the gastric acid suppression and pharmacoki-
netics of IV doses of ranitidine and famotidine were
compared in a sample of children admitted to PICU.
Methods
Patients and Dosing
A prospective, single blind randomized parallel study was
conducted in the PICU at Children’s Hospital of
Michigan. Patients 3 months to 18 years with head injury,
respiratory failure, shock, sepsis, status post major surgery
or other serious illnesses requiring mechanical ventilation
and an intravenous H2 receptor blocker were eligible.
Informed consent was obtained from the parent(s) or legal
guardian by the Principal Investigator (SM) upon arrival to
PICU. Infants 3–12 months, weighing 10 kg with
hemoglobin of 8.0 g/dL and hematocrit 24.5% were
excluded from the pharmacokinetic portion of the study to
avoid blood loss from PK sampling. However, they were
included in the pharmacodynamic portion of the study.
The study, including serial blood sampling for the
pharmacokinetics (PK) phase, was approved by the
Wayne State University (WSU) IRB.
Patients 12 months to 18 years weighing 10 kg or more
with hemoglobin and hematocrit of 8.0 g/dL and
24.5%, respectively, were enrolled for both pharmaco-
dynamic and pharmacokinetic phases. Exclusions to
participation were creatinine clearance less than 80% for
age, abdominal trauma with hollow viscus perforation,
established diagnosis of infectious, traumatic, metabolic,
or neoplastic liver disease, and use of H2 blockers 2 weeks
prior to study. Patients were randomized from a
computerized random assignment list to receive IV doses
of famotidine 12mg/m2 or ranitidine 60mg/m2 by the
Children’s Hospital of Michigan Investigational Drug
Service pharmacist who prepared and dispensed all study
drug doses.
Intragastric pH Monitoring
Gastric pH was monitored using a digital intragastric pH
probe (Digitrapper III). A 2.3mm pH microelectrode pH
probe (Zinectics single‐use pH catheters) was inserted
through the nostril to lie in midbody of the stomach.
Subjects were fasting at time of study as they were newly
admitted to PICU. Location of the probe tip was indicated
by a prompt and persistent drop in pH to less than 4.0 and
conﬁrmed. Continuous nasogastric pH probe monitoring
was performed for 18–24 hours. The pH data were
recorded on a battery‐operated portable Digitrapper III
(Synectics Medical Corp., Enﬁeld, EN) providing digital
intragastric pH reading every 4 seconds. Documentation
of an intragastric pH remaining less than 4.0 for 1 hour was
a requirement for initiating the study. Then, the ﬁrst dose
of famotidine or ranitidine was administered IV over
15minutes via a syringe device. Patients with persistent
gastric pH above 4.0 after probe placement were
disqualiﬁed from the study.
Intragastric pH was documented at times correspond-
ing to pharmacokinetic blood samples to monitor response
to study drug and determine requirement for a second
dose. A second dose of study drug was administered if
intragastric pH did not increase above 4.0 within 3 hours
of ﬁrst study drug dose or if pH decreased and remained
below 4.0 for 1 hour after initially increasing to above 4.0.
Blood sampling was discontinued following the second
dose. However, nasogastric pH monitoring continued, to
assess response and determine need for subsequent doses.
Gastric pH data were analyzed using EsopHogram
software (Medtronic, Inc., Shoreview, MN). Study
variables post infusion of the ﬁrst dose of study drug
were: pH value at time 0, area under curve (AUC) of
gastric pH (pH units multiplied by hours) at 6 and
12 hours, time (minutes) to achieve pH of 4.0, total time
pH remained above 4.0. Ratio of AUCpH to drugAUC for
12 hours after ﬁrst dose was used as a measure of relative
potency of the study drugs.
Safety Monitoring
Subjects were monitored for adverse effects commonly
related to famotidine or ranitidine, including thrombocy-
topenia, elevation of liver enzymes, and/or BUN/serum
creatinine elevations, rash, arrhythmias and documented
according to routine PICU nursing protocol. Safety labs,
including CBC with platelets, renal and hepatic function
panels, and INR and or PTT, were obtained at enrollment
and at 24 and 48 hours after administration of study drug.
Safety labs were coordinated with routine PICU blood
draws to minimize blood loss. Patients were discontinued
from study in event of intragastric pH failing to increase
above 4.0 after second dose of study drug, overt signiﬁcant
bleeding, signiﬁcant adverse reaction associated with
study drug, or parent or physician withdrew participation.
Pharmacokinetic/Pharmacodynamic Analysis. Patients
participating in both the pharmacodynamic and pharmaco-
kinetic phase had 2.5mL blood drawn at 0, 15, 30, 45,
60minutes and 2, 3, 4, 6, 10 and 16 hours post‐infusion of
the ﬁrst study drug dose. Samples were collected in oxalate
tubes, held on ice until serumwas centrifuged and stored at
70°C for ﬁnal analysis. Famotidine and ranitidine were
extracted from serum samples using solid phase extraction
techniques and analyzed by HPLC with UV detection
using a modiﬁcation of the methods of Wincek19 and
Karnes et al.20
Plasma pharmacokinetic parameters for each patient
were estimated from a non‐linear least squares ﬁt of
ranitidine or famotidine plasma concentrations versus time
to a bi‐exponential model with a 15minutes zero‐order
infusion function using PKAnalyst software (MicroMath
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Scientiﬁc, Salt Lake City, Utah). Best statistical ﬁt was
determined from Akaike information criterion. Serum
concentrations sampled between 0 and 10 hours were used
for analysis as the majority of subjects had no detectable
drug beyond 10 hours or had received a second dose
between the 10 and 16 hours sample. Terminal elimination
rate constant and terminal half‐life were determined from
the model ﬁtted. Pharmacokinetic variables including beta
half‐life, volume of distribution (Vd), maximum concen-
tration (Cmax), and clearance (Cl) were analyzed using
RSTRIP. Area under the drug concentration curve from
time 0–10 hours (AUC0–10) was obtained using the
trapezoid method. Total area (AUC0–1) was calculated
by summation of AUC0–10þCp10/ln where Cp10 is the
plasma drug concentration at 10 hours and l is the terminal
elimination rate constant. Clearance was calculated as
dose/AUC0–1 and apparent volume of distribution (Vd)
was calculated from dose/AUC ln. Relative potencies
of famotidine and ranitidine were expressed as the
respective ratios of pH AUC0–12/concentration AUC0–10.
Statistical Analysis
Descriptive statistics were used for patient characteristics
and pharmacokinetic data. Central tendency of normally
distributed data was expressed as mean SD and as
median (range) for non‐normal data sets. When assump-
tions of normality could be met Student’s t tests or one‐
way analyses of variances were used to compare differ-
ences between groups, subgroups or parameters as
appropriate. Mann–Whitney test was used for analysis
of non‐parametric data. Statistical signiﬁcance was set a
priori at p< 0.05. Analyses were conducted using SPSS
version 20.0 (IBM SPSS Statistics for Windows, Version
20.0. Armonk, NY: IBM Corp.).
Results
Thirty‐two children were enrolled with 24 children
randomized to receive either famotidine (n¼ 12) or
ranitidine (n¼ 12). Eight of 32 children did not complete
the study after randomization for the following reasons:
persistent hypochlorhydria prior to drug administration (3
children), inability to place probe (1 child), complications
unrelated to study prior to drug administration (3
children), and treatment failure after the second drug
dose (1 child). The remaining 24 subjects ranged in age
from 6 months to 16 years. Eight of the twenty‐four
children did not participate in the PK portion of the study
because of age and size; two subjects were 6months of age
and 6 were 12 months old. Diagnoses and characteristics
of the 16 study participants who completed both the PK
and PD portions of the study are summarized in Table 1.
No patient experienced any adverse effects attributable to
the study, including signiﬁcant decrease in hemoglobin
and or hematocrit. No blood transfusions were required by
any patient during the study period including those in the
PK phase. Of the 16 patients completing both the PK and
PD portions of the study, nine were randomized to receive
ranitidine and seven received famotidine (Table 2).
The two treatment groups did not signiﬁcantly differ
with respect to baseline pH values, time for median pH to
increase to pH 4.0, total time pH remained above 4.0 after
ﬁrst dose of study drug, and area under the pH versus time
curve. However, the lower famotidine dose resulted in a
mean serum concentration AUC of famotidine that was
signiﬁcantly lower than ranitidine (59,830.43 9,009.48
and 192,855.4 84,397.6 (p¼ 0.008), respectively). This
resulted in a signiﬁcant difference in the ratio of AUC pH
to AUC drug concentration from 0 to 12 hours after the
ﬁrst dose (mean ratios of 0.06849 0.01460 and
0.02453 0.01448 (p< 0.001) for famotidine and raniti-
dine, respectively), reﬂecting the greater mg for mg
potency of famotidine.
Mean PK values for famotidine and ranitidine are
summarized in Table 3. As with drug serum AUC, the
mean serum concentration maximum (Cmax) values for
famotidine were signiﬁcantly lower than for ranitidine
(963.3 230.9 and 3,291.2 917.1 ng/mL respectively;
p¼ 0.02), consistent with the lower mg/kg famotidine
dose. Calculated clearance (L/kg/h), Volume of distribu-
tion (L/kg), and half‐life did not differ between the two
treatment groups (all p values >0.05).
Discussion
Provision of optimal stress ulcer prophylaxis continues to
challenge clinicians and remains an important component
of supportive management for PICU patients. There is a
general consensus that maintaining gastric pH above 4.0 is
associated with less risk of mucosal ulceration and
bleeding in critically ill pediatric patients.3–5 However
this goal may not always be attained given the effect of
acute illness and development on pharmacodynamics and
pharmacokinetics of various agents, such as the H2
receptor blockers6–9 that are administered to decrease
gastric acid production.
Harrison and coworkers demonstrated that administer-
ing usual therapeutic doses of ranitidine to critically ill
children may not provide adequate gastric pH control.17 In
addition to the effects of immaturity, children in the PICU
often have organ function further compromised by disease,
affecting drugmetabolism and response to therapy.9,11–15,21
Gastric pH monitoring, individualization of H2 receptor
blocker therapy, use of continuous infusion regimens, and
selection of the most effective H2 blocker may improve
clinical outcomes in stress ulcer prophylaxis.2,16,17
The present study conﬁrmed the greater potency of
famotidine compared to ranitidine in critically ill children,
similar to what has been demonstrated in previous
studies.2–5 However, greater potency does not necessarily
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mean superior efﬁcacy or clinical superiority. In this study,
both agents were shown to be effective in gastric acid
suppression in PICU patients. Nevertheless, greater
potency does allow for less systemic exposure to the
drug to achieve the same pharmacodynamic effect and
may translate to clinical advantage if this decreases
adverse effects or allows less frequent dosing. The lower
dose and less frequent dosing of famotidine relative to
ranitidine may offer potential advantages for the PICU
population in terms of medication cost savings, less line
access, nursing and pharmacy time and adverse effects.
Famotidine therapy also avoids risk of ranitidine induced
thrombocytopenia.4
Several pharmacokinetic parameters in our PICU
sample (including mean Cl value for famotidine
0.53 0.17 L/h/kg; half‐life 2.25 1.1 hours) were simi-
lar to those reported in the general pediatric population
(mean Cl 54 0.34 L/h/kg, half‐life 2.3 1.3).7,8 Con-
versely, the calculated mean volume of distribution (Vd)
for both agents was lower than reported in previous
investigations. Several factors may have contributed to
this difference. Our patients received a maximum of two
H2 receptor doses equivalent to 0.5mg/kg famotidine and
2mg/kg ranitidine during the study and were not at steady
state concentrations at the time of sampling. The low Vd
value may reﬂect use of diuretics and strict ﬂuid
monitoring in our PICU sample which included a
disproportionate number (63%) of cardiac surgery
patients. In addition to ﬂuid restriction, these infants
and children often have decreased renal and hepatic blood
ﬂow.21 However the inclusion criteria for the present study
stipulated normal renal function upon entry therefore our
patients did not have documented renal compromise. The
half‐life of famotidine has been shown to be longer
compared to ranitidine in previous studies of both children
and adults.4,5,7,8 In contrast, we did not observe a
signiﬁcant difference in half‐life or Cl between the two
drugs in our sample of critically ill children. Furthermore,
we did not see a signiﬁcant difference in duration of acid
suppression between the two drugs.
There are several limitations to our study including lack
of monitoring until steady state serum concentrations were
Table 1. Characteristics of Subjects Completing Both PK and PD Portions of Study (n¼ 16)
Characteristic Famotidine (n¼ 7/16) Ranitidine (n¼ 9/16)
Diagnosis
Cardiovascular surgery 5/7 5/9
Posterior spinal fusion 1/7 3/9
Neurosurgery (brain) 0/7 1/9
Status epilepticus 1/7 0/9
Age (mean SD, years) 4.7 3.9 6.6 4.7 (p¼ 0.39)
Weight (mean SD, kg) 20.4 8.1 26.6 15.9 (p¼ 0.33)
Ethnicity 3 white, 3 black, 1 middle Eastern 2 white, 7 black
Gender (male/female) 2/5 4/5
Table 2. Pharmacodynamic Data (n¼ 16)
Group pHa: 0, 6, 12 (hours) Time (minutes) pH 4.0, pH< 4.0 AUC pH AUC pH/AUC drugb,c
Famotidine 2.7, 7.1, 7.0 25.5, 563 3,836.45 741.46 0.0685 0.01460 (n¼ 7)
Ranitidine 2.3, 6.7, 5.0 26.5, 543 3,966.4 664.92 0.0245 0.01448 (n¼ 9)
aMedian values unless indicated; pH similar between groups (p¼ 0.2).
bMean SD values.
cp 0.001, Mann–Whitney test.
Table 3. Pharmacokinetic Parameters of Famotidine and Ranitidinea (n¼ 16)
Group Cmax (ng/mL) t1/2 (hours) Cl (L/h/kg) Vd (L/kg) AUC drug (mg/mL)
Famotidine 963.3 230.9b 2.25 1.1 0.53 0.17 0.38 0.23 59,830.53 9,009.5 (n¼ 7)
Ranitidine 3,291.2 917.1 1.67 1.2 0.77 0.41 0.45 0.20 192,855.44 84,397.6c (n¼ 9)
aMean SD values.
bCmax p¼ 0.02.
cAUC drug p¼ 0.008.
t1/2, p¼ 0.5; Cl, p¼ 0.16; Vd, p¼ 0.3.
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achieved. However performing a longer‐term study in
PICU over several days in critically ill, unstable patients
was not practical. We did not compare the acuity of illness
or concomitant medications between study groups. In
addition, concomitant medications were not examined and
analyzed for potential drug interactions with the study
agents. A child in PICU may be exposed to 20 or more
medications per day.11 Without these data we were unable
to account for the effect of acuity of illness and other
medications on the acid suppression efﬁcacy in addition to
the PK parameters of the study agents. Maximal effect at
steady state of these H2 receptor blockers was not
compared although peak effect occurs within 3 hours after
IV doses of these agents.4,7–9 Intragastric pH probe
monitoring is limited when the probe is misplaced or
meals interfere with pH reading. These technical
limitations were mitigated as our subjects were fasting,
receiving mechanical ventilation and had probe placement
radiographically conﬁrmed.
Conclusion
It is important to characterize the pharmacokinetics and
pharmacodynamics of medications that are used in these
complex, high risk patients. At present there are no
pediatric dosing regimens based on PK or PD for stress
ulcer prophylaxis therapies other than increasing dosage
of H2 receptor blockers to maintain an elevated gastric pH.
The American Society of Health‐System Pharmacists
(ASHP) published the only available guidelines in 1999
addressing use of stress ulcer prophylaxis in pediatric ICU
patients.4 These guidelines are under revision and will be
published during 2013. This study provides pharmacoki-
netic/pharmacodynamic data on ranitidine and famotidine
to assist in selection and dosing of these two H2 blockers
in PICU patients.1–4
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